Silo Wellness Inc. (CSE: SILO | OTCQB: SILFF | FSE: 3K7A), a leading global psychedelics company, and Dyscovry Science Ltd. (“Dyscovry”), a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome, today announced the companies have entered into a definitive share exchange agreement through which…